Insider Selling: Artivion, Inc. (NYSE:AORT) CEO Sells 42,156 Shares of Stock

Artivion, Inc. (NYSE:AORT) CEO James P. Mackin sold 42,156 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at $18,130,617.42. This represents a 5.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artivion Trading Down 0.2 %

Artivion stock opened at $25.38 on Friday. Artivion, Inc. has a 12-month low of $18.38 and a 12-month high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a market capitalization of $1.06 billion, a PE ratio of -1,268.85 and a beta of 1.75. The firm has a 50 day simple moving average of $29.63 and a 200-day simple moving average of $27.81.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). The firm had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Oppenheimer increased their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Needham & Company LLC dropped their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday. Stifel Nicolaus reduced their price objective on Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, JMP Securities restated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $31.40.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its position in shares of Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after purchasing an additional 786 shares in the last quarter. Quarry LP lifted its stake in Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after purchasing an additional 820 shares during the last quarter. R Squared Ltd acquired a new stake in Artivion during the fourth quarter valued at approximately $39,000. Arcadia Investment Management Corp MI bought a new stake in Artivion during the fourth quarter worth approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Artivion in the fourth quarter worth approximately $64,000. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.